Low dose of Rotigotine in post-stroke patients with vascular parkinsonism and obstructive sleep apnoea syndrome, effects on quality of life and rehabilitation therapy [PDF]
, 2017 Stroke is a frequent cause of disability in U.S.A. (200.000/ year). Aim: The aim of this study is to underline the effect of low dose of Rotigotine patches 2 mg/24 h, a complete dopamine agonist with continuous dopaminergic stimulation through the ...
Ceratti U +7 more
core +1 more source
Neuroimaging in Functional Movement Disorders. [PDF]
, 2019 PURPOSE OF REVIEW: Functional movement disorders are common and disabling causes of abnormal movement control. Here, we review the current state of the evidence on the use of neuroimaging in Functional movement disorders, particularly its role in helping
Edwards, MJ, Roelofs, JJ, Teodoro, T
core +2 more sources
Predictors of functional dependency in Parkinson’s disease [PDF]
, 2016 Financial disclosures/conflicts of interest: Dr Macleod was funded by a Clinical Academic Fellowship from the Chief Scientist Office of the Scottish Government and received grant funding from Parkinson’s UK, the Wellcome Trust, University of Aberdeen ...
Adler +33 more
core +1 more source
Myoclonus-dystonia : distinctive motor and non-motor phenotype from other dystonia syndromes [PDF]
, 2019 Background: myoclonus-dystonia (M-D) due to a pathogenic variant of SGCE is an autosomal dominant inherited movement disorder. Apart from motor symptoms, psychiatric disorders are highly prevalent in patients with MD.
Bartels, Anna L. +8 more
core +2 more sources
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates [PDF]
, 1993 Degeneration of nigrostriatal dopaminergic neurons is the primary histopathological feature of Parkinson's disease. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces a neurological syndrome in man and non-human primates very ...
Burg, M. +7 more
core +1 more source
Rates of lobar atrophy in asymptomatic MAPT mutation carriers. [PDF]
, 2019 IntroductionThe aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule-associated protein tau (MAPT) mutation carriers.MethodsMAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from ...
Boeve, Bradley F +24 more
core +2 more sources
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases [PDF]
, 2017 Objective: To examine the utility of the new Movement Disorder Society (MDS) diagnostic criteria in a large cohort of Parkinson's disease (PD) patients.
, +13 more
core +5 more sources
Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]
, 2017 Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger +25 more
core +1 more source
Metoclopramide Neurological Side Effects Screening; A Pharmacovigilence Study in Romanian Community Pharmacies [PDF]
, 2015 Background. Metoclopramide is a pharmacological agent frequently used in therapy against nausea and vomiting that can occur in indigestion, motion sickness, gastric ulcer, pyloric spasm and after surgery as a side effect of some anesthetics.
Junghină, Adrian +4 more
core +4 more sources